David Boles

Profil David Boles

David Boles has extensive experience advising clients on capital markets and securities regulation matters. He represents issuers, investment banks and investors on initial public offerings, private placements and other equity capital markets transactions across Europe, the Middle East and Africa, including US-registered offerings by foreign private issuers.

He represents issuers active in a wide range of industries, including life sciences, technology, e-commerce, financial services, fintech, retail and consumer. David is consistently named as a leading individual for equity capital markets work by publications in the UK, including IFLR1000 and Legal 500.

Mandate

• Advising Excientia on its $510.4 million IPO and Nasdaq listing.*
• Advising Valneva SA on its $107.6 million IPO and Nasdaq listing and $102.0 million follow-on offering.*
• Advising WeTransfer (The Creative Productivity Company) on its intended IPO and Euronext Amsterdam listing.*
• Advising Pharming Group NV on its direct listing on Nasdaq.*
• Advising the underwriters on the $113.3 million IPO and Nasdaq listing of Nanobiotix SA.*
• Advising the underwriters on the $146.6 million IPO and Nasdaq listing of Compass Pathways.*
• Advising the underwriters on the $93.7 million IPO and HYSE listing of Via Optronics AG.*
• Advising Bavarian Nordic on its DKK2.7 billion Rights Offering on the Nasdaq Copenhagen.*
• Advising RenalytixAI on its $85 million IPO and listing on Nasdaq.*
• Advising the underwriters on the $200 million PIPE of Verona Pharma.*
• Advising the underwriters on the $244.8 million follow-on offering of Adaptimmune Therapeutics.*
• Advising Zealand Pharma on its $98.7 million ABB and PIPE.*
• Advising the underwriters on the €300 million IPO and listing of Global Fashion Group on the Frankfurt Stock Exchange.*
• Advising the underwriters on the US$280 million IPO and concurrent private placement of Jumia Technologies on the NYSE.*
• Advising HeadHunter Group on its US$253 million IPO and listing on NASDAQ.*
• Advising the underwriters on the €150 million IPO of home24 on the Frankfurt Stock Exchange.*
• Advising Siemens Healthineers on its €4.2 billion IPO on the Frankfurt Stock Exchange.*
• Advising the underwriters on the €947 million IPO of Adyen on Euronext Amsterdam.*
• Advising the underwriters on the US$240 million US-registered offering and secondary listing of MorphoSys.*
• Advising TI Fluid Systems on its £407 million IPO on the London Stock Exchange.*
• Advising the underwriters on the €377 million IPO of Dermapharm Holding on the Frankfurt Stock Exchange.*
• Advising the underwriters on the €318 million IPO of HelloFresh on the Frankfurt Stock Exchange.*

*Transaction handled prior to joining Freshfields